Recovery time in no treatment: 25 days. Recovery time in HCQ+AZM: 9 days.
Another brick in the HCQ evidence wall
-
Turkey has one of the lowest death rates in the world because of early HCQ use.
https://www.al-monitor.com/pulse/originals/2020/04/turkey-outbreak-peak-gov-ease-restrictions.html
Among the factors behind the improvement are Turkish doctors’ experimental uses of drug therapies, Koca said. They have found the drug hydroxychloroquine reduces symptoms and damage caused by the virus, and the government stockpiled the decades-old malaria treatment before Turkey's first case was confirmed on March 11.
Hydroxychloroquine has stirred controversy elsewhere, especially in the United States, where President Donald Trump plugged the drug despite a lack of research into its efficacy in treating COVID-19. Fears it may cause serious cardiac issues or blindness prompted US regulators to caution against its use last week.
Turkey appears to be using hydroxychloroquine outside of clinical trials.
-
https://www.medrxiv.org/content/10.1101/2020.04.27.20073379v1
Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19
CONCLUSIONS AND RELEVANCE: Hydroxychloroquine treatment is significantly associated with a decreased mortality in critically ill patients with COVID-19 through attenuation of inflammatory cytokine storm. Therefore, hydroxychloroquine should be prescribed for treatment of critically ill COVID-19 patients to save lives.
-
Head of the Saudi Patient Safety Counsel got COVID, recovered after taking HCQ
Within 24 hours, my results came back positive for COVID-19. I have to admit that, even though I couldn’t remember being exposed to any suspected or confirmed COVID-19 patients, I wasn’t surprised to be positive for two reasons:
1) My symptoms were so severe, which was very unusual for someone like me who hardly gets a mild cold.
2) My body’s response to Hydroxychloroquine was so pronounced. With the first 2 doses of it, I had shaking and chills for 30 minutes every time I took it.
36 hours after I was started on the Hydroxychloroquine, my fever subsided, and my other symptoms started to improve. The pleuritic chest pain continued for about 7 days. but eventually receded.
-
https://www.medrxiv.org/content/10.1101/2020.04.26.20081059v1
The median time to achieve an undetectable viral RNA was shorter in chloroquine than in non-chloroquine (absolute difference in medians -6.0 days; 95% CI -6.0 to -4.0). The duration of fever is shorter in chloroquine (geometric mean ratio 0.6; 95% CI 0.5 to 0.8). No serious adverse events were observed in the chloroquine group. Patients treated with half dose experienced lower rate of adverse events than with full dose. Conclusions Although randomised trials are needed for further evaluation, this study provides evidence for safety and efficacy of chloroquine in COVID-19 and suggests that chloroquine can be a cost-effective therapy for combating the COVID-19 pandemic.
-
However, it should be pointed out that remdesivir is supposed to act as an antiviral, so it should have the greatest effect in the early stages of the infection. Giving it to already seriously ill patients several weeks out is kind of pointless as by then the virus replication has gone out of control - which the drug is supposed to prevent. The same holds for HCQ trials, btw.
-
The hits just keep on coming.
https://www.preprints.org/manuscript/202005.0057/v1
Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study
We enrolled all 18-85 years old inpatients from Central Defense Hospital “Gómez Ulla”, Madrid, Spain, who were hospitalised for COVID-19 and had a definitive outcome (dead or discharged). We used a statistical survival analysis to detect treatment differences associated with in-hospital death. Results: We analysed first 220 medical records. 166 patients met the inclusion criteria. 48,8 % of patients not treated with HCQ died, 22% of those treated with hydroxychloroquine (p=0,002). According to clinical picture at admission, hydroxychloroquine increased the mean cumulative survival in all groups from 1,4 to 1,8 times. This difference was statistically significant in the mild group.
Conclusions: in a cohort of 166 patients from 18 to 85 years hospitalised with COVID-19, hydroxychloroquine treatment with 800mg added loading dose increased survival when patients were admitted in early stages of the disease. There was a non-statistically significant trend towards survival in all groups, which will have to be clarified in subsequent studies.